« Return to News | R&D Trends | Drug Sponsors

Bristol-Myers Squibb to acquire Inhibitex

Monday, January 9, 2012 03:59 PM

Bristol-Myers Squibb has agreed to acquire Inhibitex, a biopharmaceutical company, for $26 per share, or approximately $2.5 billion, in cash.

Inhibitex, most known for its focus on drugs that prevent and treat hepatitis C, has given Bristol-Myers Squibb (BMS) INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. BMS will also acquire two other products in phase II development (FV-100 and Aurexis) and several other fully developed products that prevent and treat serious infection diseases.

"The addition of Inhibitex's nucleotide polymerase inhibitor to our own promising portfolio, which includes other direct-acting antivirals, brings additional options to develop all-oral regimens with better cure rates, shorter duration of therapy and lower toxicity than the current standard of care,” said Elliott Sigal, M.D., Ph.D., chief scientific officer for BMS.

BMS announced a cash tender offer to purchase all outstanding shares of Inhibitex’s common stock for $26 per share.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.